logo

For the Inventor, By the Inventor

Langley, Canada

Anormed, Inc.


USPTO Granted Patents = 40

% Expired Patents = 22.5



Forward Citations = 749

Loading Chart...
Loading Chart...

50 inventors (with patents filed for the assignee):

goldMedal Gary James Bridger (23 out of 45 patents)

silverMedal Renato Skerlj (19 out of 33 patents)

bronzeMedal Dominique Schols (16 out of 31 patents)

4.  David Earl Bogucki (15 out of 32 patents)

5.  Ernest John McEachern (13 out of 43 patents)

6.  Trevor R Wilson (11 out of 16 patents)

7.  Jason B Crawford (11 out of 18 patents)

8.  Curtis Harwig (10 out of 32 patents)

9.  Yuanxi Zhou (10 out of 40 patents)

10.  Al Kaller (10 out of 18 patents)

11.  Siqiao Nan (10 out of 16 patents)

12.  Bem Atsma (8 out of 12 patents)

13.  Michael J Abrams (7 out of 32 patents)

14.  Christopher Dennis Smith (5 out of 9 patents)

15.  Eva Maria Boehringer (5 out of 7 patents)


Core Competencies:
Chemokine Receptors
Antiviral Compounds
Stem Cell Mobilization
Amino-Substituted Rings
CXCR4 Antagonist
Platinum Complexes
Immunosuppressive Compositions
Cytokine Inhibitors
Pharmaceutical Compositions
Bicyclic Rings
Antitumor Agents
Substituted Azaspiranes

40 patents:

1. 7452994 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2008-11-18),
2. 7354934 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),
3. 7354932 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy (2008-04-08),
4. 7332605 - Process for the synthesis of CXCR4 antagonist (2008-02-19),
5. 7312234 - Chemokine receptor binding heterocyclic compounds (2007-12-25),
6. 7183273 - Chemokine receptor binding heterocyclic compounds (2007-02-27),
7. 7169750 - Methods to mobilize progenitor/stem cells (2007-01-30),
8. 7160872 - Methods to treat conditions mediated by chemokine receptors (2007-01-09),
9. 7135570 - Synthesis of enantiomerically pure amino-substituted fused bicyclic rings (2006-11-14),
10. 7091217 - Chemokine receptor binding heterocyclic compounds (2006-08-15),
11. 7084155 - Chemokine receptor binding heterocyclic compounds (2006-08-01),
12. 7022717 - Chemokine receptor binding heterocyclic compounds (2006-04-04),
13. 6987102 - Methods to mobilize progenitor/stem cells (2006-01-17),
14. 6894049 - Platinum complexes as antitumor agents (2005-05-17),
15. 6872714 - Methods to modulate conditions mediated by the CXCR4 receptor (2005-03-29),
Anormed, Inc., based in Langley, Canada, specializes in the development of innovative therapeutic agents targeting various medical conditions. The company focuses on advanced research in areas such as chemokine receptor binding and progenitor cell mobilization, with a particular emphasis on CXCR4 antagonists. Their portfolio includes antitumor agents and antiviral compounds, leveraging unique technologies involving amino-substituted bicyclic rings and platinum complexes to enhance white blood cell function and improve treatment outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Anormed, Inc.
40 Patents

#1 in Langley

#344 in Canada

#17,031 in the World

Langley, CA
Langley, Canada

Anormed, Inc.

Forward Citations = 749

50 inventors:

goldMedal Gary James Bridger (23 out of 45 patents)

silverMedal Renato Skerlj (19 out of 33 patents)

bronzeMedal Dominique Schols (16 out of 31 patents)

4.  David Earl Bogucki (15 out of 32 patents)

5.  Ernest John McEachern (13 out of 43 patents)

Please report any incorrect information to [email protected]
Loading…